The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Original story from Drug Target Review.
Technical innovation enables rapid assessment of T cell repertoires for research and diagnostics, with potential applications in studying COVID-19 immune responses.
Original story from UCSC Newscenter.
While doctors and nurses treat COVID-19 patients on the front lines, behind the scenes scientists are working hard in their labs to come up with ways to battle the pandemic. A team of UC Santa Cruz scientists are targeting high capacity coronavirus diagnostic testing with 24-hour turnaround that will meet the needs of community in the County of Santa Cruz.
Original story from KSBW.
An NIH-funded team has some new clues based on evidence showing how a molecular “switch” wired into the biological clocks of extreme early risers leads them to operate on a daily cycle of about 20 hours instead of a full 24-hour, or circadian cycle.
Original story from NIH Director’s Blog.
Palbociclib is clinically approved for use in treating breast cancer, but according to a new study, the molecular mechanism behind the drug’s effectiveness is not what scientists had thought it was.
Original story from UCSC Newscenter.
UCSC Newscenter — All alumnus Patrick Bailey needed was some support, which he found in the Summer Research Experience program at UC Santa Cruz; this year, he defied the odds by earning a Ph.D. in Biochemistry & Molecular Biology, and is now doing cancer research.
Medical Xpress — A collaboration between researchers from Brazil and the United States may open new avenues for the treatment of thrombosis, the leading cause of death among cancer patients. In a study to be published in Blood, the scientists describe the Ixolaris structure, an important anticoagulant protein found in tick saliva, and its interaction with Factor Xa, a key enzyme in the process of blood clotting.
